Glaukos (NYSE:GKOS) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Glaukos (NYSE:GKOS) in a report issued on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $103.00 price target on the medical instruments supplier’s stock.

Other equities research analysts also recently issued reports about the company. UBS Group upped their target price on Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Wells Fargo & Company raised their target price on Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. BTIG Research reiterated a “buy” rating and issued a $118.00 price target on shares of Glaukos in a research report on Wednesday, September 10th. Finally, William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $122.00.

Glaukos Price Performance

Shares of NYSE GKOS opened at $87.45 on Wednesday. The stock has a market cap of $5.02 billion, a P/E ratio of -53.00 and a beta of 0.76. The firm’s 50-day simple moving average is $88.50 and its 200 day simple moving average is $93.39. Glaukos has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter in the prior year, the firm posted ($0.52) EPS. Glaukos’s revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities analysts expect that Glaukos will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 327 shares in the last quarter. GAMMA Investing LLC grew its position in Glaukos by 5,912.8% during the 1st quarter. GAMMA Investing LLC now owns 133,064 shares of the medical instruments supplier’s stock worth $13,096,000 after purchasing an additional 130,851 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Glaukos by 59.5% during the 1st quarter. Harbor Capital Advisors Inc. now owns 39,132 shares of the medical instruments supplier’s stock worth $3,851,000 after purchasing an additional 14,593 shares in the last quarter. SG Americas Securities LLC raised its stake in Glaukos by 35.2% during the 1st quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier’s stock valued at $485,000 after purchasing an additional 1,283 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Glaukos by 25.2% in the first quarter. Handelsbanken Fonder AB now owns 18,400 shares of the medical instruments supplier’s stock valued at $1,811,000 after purchasing an additional 3,700 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.